Key Takeaways
- DSO partnership agreements set your cash at close, rollover equity, clinical autonomy, and long-term economics, so you need to understand these terms before signing.
- Key negotiable provisions include cash-at-close percentages, management fees (typically 22–32%), employment terms, restrictive covenants, and buyout or change-of-control clauses.
- Owners can prioritize clear clinical autonomy language, fair-market-value redemption formulas, and protections against DSO-controlled variables that could reduce earnouts or equity value.
- State-specific rules, such as California’s SB 351 effective January 1, 2026, add new restrictions on non-competes and clinical interference that must be addressed in every agreement.
- McLerran & Associates uses a competitive bid process and CPA-led diligence to help dental owners negotiate stronger terms; learn how our process protects your practice value.
Cash at Close and Rollover Equity Structure
Cash at close is the guaranteed, liquid portion of your purchase price paid on the day the deal funds. Rollover equity, sometimes called a “second bite of the apple,” is the percentage of your proceeds converted into ownership shares in the DSO's parent company, which remain illiquid until the platform is sold or recapitalized, typically five to seven years later.
Cash at close can be some of the main factors determining how much liquidity you receive immediately, with the balance often split between earnouts and rollover equity. Rollover equity in DSO HoldCo structures commonly ranges from 15% to 40% of the purchase price, and it generates no regular distributions. Returns depend entirely on the platform's growth and the valuation at exit.
Owner priorities: Push for the highest achievable cash-at-close percentage. Clarify whether your equity sits at the joint-venture (practice) level, which can generate profit distributions, or at the holding-company level, which can offer a higher ceiling but no current income.
Red flag: Liquidation preferences and senior debt ahead of your rollover equity can consume most or all of its value at exit, which is why transparency matters. Any DSO that refuses to disclose its current leverage ratio and liquidation waterfall in plain language is signaling that the numbers may not work in your favor.
McLerran & Associates controls the narrative around your EBITDA, meaning the practice's true earnings before interest, taxes, depreciation, and amortization, through a CPA-led analysis completed before the deal goes to market. That diligence-grade foundation, combined with a competitive bid process that typically generates around 10 offers in 45 to 60 days, creates the leverage needed to push cash-at-close percentages toward the top of the market range.
Management Fee and Profit Distribution Terms
Once you have clarity on your cash and equity mix, the next major driver of your long-term economics is the management fee and how it affects your ongoing profit distributions. The management fee is the monthly charge the DSO's management services organization (MSO) deducts from your practice's revenue in exchange for administrative support, including billing, HR, payroll, compliance, and IT. What remains after that fee and operating expenses is your profit distribution.
Management fees in 2026 DSO MSAs are typically set at 22% to 32% of collections, though the scope of services covered can vary widely. Most state laws require the fee to be set at fair market value, and percentage-of-revenue structures face heightened scrutiny in states like California under fee-splitting rules.
Owner priorities: Negotiate the fee against a clearly defined service schedule. Confirm what the DSO is actually delivering for that percentage, and ensure the fee adjusts downward if services are reduced.
Red flag: Many MSAs include a management fee floor that maintains the DSO's dollar fee even if practice collections decline, for example due to a payer dispute, which can squeeze your local profit and loss statement. Negotiate the floor out or tie the fee strictly to actual collections.
Clinical Autonomy and Key MSA Protections
The Management Services Agreement (MSA) is the contract between the DSO's business entity and your dentist-owned professional corporation. It defines which decisions belong to you and which belong to the DSO. Clinical autonomy provisions affirm that diagnosis, treatment planning, patient care protocols, and the hiring of clinical staff remain exclusively under your control as the licensed professional.
A properly drafted MSA can contain explicit clinical autonomy provisions affirming that the dental practice retains 100% control over all clinical decisions. Vague or absent language in this section can be one of the most consequential gaps an owner might overlook.
Owner priorities: Require specific, affirmative language, not just silence, protecting your authority over treatment planning, lab and material selection, scheduling flow, and clinical staffing. Because DSOs often push for scheduling changes during integration, well-negotiated 2026 deals include scheduling-flow autonomy protections for the first 12 to 18 months post-close, which gives you time to demonstrate that your existing model works before any adjustments occur.
Red flag: Any MSA language granting the DSO authority over patient volume, hours worked by clinicians, or referral decisions is a structural problem, not a minor drafting issue.
Employment Term and Doctor Compensation
After a DSO affiliation, the selling dentist typically transitions from owner to employed associate under a post-closing employment agreement. This document governs how long you are required to practice, what you are paid for clinical production, and what triggers early termination.
Doctor-employment agreements are common in DSO transactions, with typical terms of 1 to 5 years. Post-close clinical compensation is typically a percentage of personal collections, which can reduce owner take-home pay compared to prior owner distributions unless you negotiate separate protections.
Owner priorities: Negotiate the compensation percentage before signing the letter of intent (LOI), meaning the preliminary agreement that sets the framework for the full deal, because it rarely improves afterward. Push for a termination-without-cause provision that accelerates any unvested earnout or equity.
Red flag: Employment agreements that tie your compensation solely to production without accounting for DSO-controlled scheduling or staffing decisions can create a situation where your income falls through no fault of your own.
McLerran & Associates produces multi-year financial forecasting that models your real after-tax income across the employment period. This approach allows you to compare what you net under a DSO employment structure versus keeping the practice for another 3 to 5 years.
Restrictive Covenants and Tail Coverage Details
Restrictive covenants, primarily non-compete and non-solicitation clauses, define where and for how long you cannot practice after the affiliation ends. Tail coverage refers to malpractice insurance that covers claims arising from treatment rendered before the sale closes.
Non-compete geographic scope in dental DSO agreements typically targets a reasonable radius, with buyers often initially proposing 25 or more miles. Duration is often 2 to 3 years, with buyers sometimes initially proposing 7 or more years, while recommended negotiated terms are 2 to 3 years.
Owner priorities: Limit the radius to a defensible patient draw area, not an arbitrary boundary. Require a carve-out that voids the non-compete if the DSO terminates you without cause. Confirm who pays for tail coverage and for how long.
Red flag: DSO non-competes that apply to all current and future office locations across a multi-location organization can effectively blacklist a dentist from an entire metro area, and courts are increasingly skeptical of such multi-location stacking provisions.
State law governs enforceability and varies significantly. California's Business and Professions Code § 16600 voids virtually every employee non-compete, though a sale-of-business exception under § 16601 can bind a selling owner to a geographic restriction. Utah's HB 270, effective May 6, 2026, voids healthcare non-compete agreements for dentists in employment contexts, though sale-of-business restrictions remain enforceable if reasonable. McLerran works with dental-specific legal counsel in every market so restrictive covenant terms reflect current state law.
Buyout and Change-of-Control Provisions
While restrictive covenants govern what happens when you leave the DSO, change-of-control provisions determine what happens to your rollover equity and employment agreement if the DSO itself is sold to another buyer. This outcome is common, given that private equity sponsors typically exit platforms within the timeframe discussed earlier. A buyout provision defines the price and process by which you can redeem your equity before a platform sale occurs.
Owner priorities: Rollover redemption rules in typical DSO deals often redeem equity at book value if a seller leaves before a platform sale. Negotiate a formula tied to trailing 12-month EBITDA and the platform multiple to preserve fair market value. Push for double-trigger acceleration, meaning your unvested equity vests immediately if the DSO is sold and your employment is terminated.
Red flag: Drag-along rights commonly force sellers to participate in a later sponsor sale of the platform. Review approval thresholds and preferred return structures carefully so you understand your actual proceeds at exit.
McLerran's competitive bid process creates leverage at the LOI stage, before these provisions are locked, because a DSO that knows other qualified buyers are at the table is more willing to negotiate governance protections and fair buyout formulas.
Get expert analysis of the change-of-control terms in your offer. McLerran & Associates will review how these provisions could affect your long-term economics.
Debt and CapEx Controls After Closing
Debt controls govern how much leverage, meaning borrowed money, the DSO can place on the platform that holds your rollover equity. Capital expenditure (CapEx) controls define who approves major equipment purchases or facility investments at your practice location after closing.
Owner priorities: Require buyers to disclose in plain language the liquidation preferences, current leverage ratio, and anticipated exit timeline, because opaque debt terms can render your retained equity worth far less than represented at signing. Beyond understanding the platform's existing debt, you also need visibility into future spending decisions, so negotiate approval rights or at minimum notification rights for CapEx decisions above a defined threshold at your location, since major equipment purchases can affect both your practice's profitability and the DSO's overall leverage.
Red flag: Earnout structures in DSO deals can be structurally risky when the buyer controls post-close expenses, headcount, and pricing, because those decisions directly determine whether your EBITDA targets can be achieved. If the DSO can load costs onto your practice's profit and loss statement after closing, your earnout may be unreachable through no fault of your own.
McLerran's quality-of-earnings defense, meaning the process of protecting the EBITDA figure agreed at LOI when the buyer's diligence team scrutinizes the numbers, extends through closing, and the firm reminds buyers that other vetted bidders remain available if they attempt to re-trade the deal.
Frequently Asked Questions
What is the difference between holding-company equity and joint-venture equity in a DSO deal?
Joint-venture equity means you retain an ownership stake at the practice level. This structure typically generates ongoing profit distributions after the management fee is paid, which provides current income during your employment period. Holding-company equity, by contrast, means your rollover converts into shares of the DSO's parent entity. As noted earlier, holding-company equity pays no current income, and your return depends on the exit valuation when the sponsor sells or recapitalizes. The holding-company structure offers a potentially higher ceiling but a lower floor, and it requires you to underwrite the DSO itself as an investment. McLerran helps owners model both structures across multiple time horizons so the comparison is based on real after-tax numbers rather than headline figures.
How does an earnout work, and what protections should I negotiate?
An earnout is a contingent payment tied to your practice's financial performance over a defined period after closing, commonly 12 to 36 months. If the practice hits agreed targets, you receive the earnout. If it falls short, you may receive a reduced amount or nothing. The core risk is that the DSO controls many of the variables, including staffing, scheduling, expenses, and payer contracts, that determine whether those targets are achievable. Protections to negotiate can include a pro-rata provision so that near-misses still pay a proportional amount, carve-outs excluding buyer-initiated changes from the target calculation, and a later start date to account for the integration period before your practice is running at full capacity under the new structure.
Are non-compete clauses in DSO agreements enforceable in California?
California's Business and Professions Code § 16600 voids virtually all employee non-compete agreements, which makes them unenforceable in most employment contexts. However, a narrow sale-of-business exception under § 16601 can bind a selling owner to a geographic non-compete when they sell the goodwill or ownership interest in their practice to a DSO. This structure means the non-compete may be enforceable against you as the selling dentist even though it would not bind your employees. California's SB 351, effective January 1, 2026, adds further restrictions on what private equity-backed MSOs can include in management agreements and voids certain non-compete and non-disparagement clauses in that context. Given the complexity and the pace of legislative change in California, owners can benefit from working with dental-specific legal counsel alongside a sell-side advisor who understands the current regulatory environment.
What does “good-leaver” mean in a DSO MSA, and why does it matter?
A good-leaver definition specifies the circumstances under which a departing dentist retains their rollover equity at fair market value rather than having it redeemed at a discounted or book value. Common good-leaver triggers include death, permanent disability, and non-renewal of the employment agreement by the DSO. The definition can matter enormously because if you leave for a reason not covered, such as burnout, a family health situation, or retirement before a specified age, you may forfeit a significant portion of your equity. Owners can push to include retirement after a defined age, typically 60, as a good-leaver event and to tie the redemption formula to a trailing EBITDA multiple rather than book value.
How does McLerran & Associates create competition in a DSO sale process?
McLerran runs a structured, auction-like bid process among a vetted pool of well-qualified DSO and private equity buyers, typically generating multiple qualified offers within the 45-to-60-day timeline mentioned earlier. The firm builds a diligence-grade marketing deck and virtual data room before going to market, so buyers are working from the same defensible EBITDA analysis rather than their own assumptions. Poorly run or undercapitalized DSOs are blacklisted and never reach the table. The competitive environment means that no single buyer can anchor the price or dictate terms unilaterally, and it gives McLerran the leverage to push for stronger cash-at-close percentages, more favorable earnout structures, and stronger clinical autonomy protections than an owner negotiating with one buyer alone could achieve.
Conclusion: Protect Your Practice Value with the Right Partner
The seven DSO partnership agreement terms dental owners face in 2026, including cash at close, rollover equity, management fees, clinical autonomy, employment terms, restrictive covenants, buyout provisions, and debt controls, are not boilerplate. Each one is negotiable, and each one can have a material effect on both your exit economics and your clinical future. A DSO negotiates these terms every week. You negotiate them once.
McLerran & Associates is the sell-side advisor and advocate that levels that table. With more than 10,000 practices evaluated, a CPA-led EBITDA process that holds up under buyer scrutiny, and a competitive bid process that creates real market tension, the firm does more than list practices, it sells them. Clients typically achieve valuations approximately 30% higher than owners who go it alone, and McLerran's transaction rate of roughly 85% to 90% compares to an industry norm closer to 35% to 40%.
If you are weighing a DSO affiliation now or in the next few years, the time to understand your options and build your position is before you receive an offer, not after.
Start the conversation about your practice transition and discuss your goals and what the 2026 market can mean for your specific situation. Call (512) 900-7989 or email info@dentaltransitions.com.
